Emixustat Sales Forecast And Market Size Analysis Report 2026-2034 With Focus On United States, Germany, France, Italy, Spain, United Kingdom, And Japan

(MENAFN- GlobeNewsWire - Nasdaq) Emixustat presents significant market potential due to its novel mechanism targeting unmet needs in retinal diseases like geographic atrophy and Stargardt. Its oral administration enhances patient compliance compared to injectable therapies. Focus on rare diseases offers orphan designations and pricing benefits, supporting long-term adoption.

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Emixustat Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets's offering.

Emixustat, developed by Acucela, targets retinal degenerative diseases by inhibiting RPE65, moderating toxic byproducts such as A2E. This oral treatment, evaluated at variable dosages, impacts rod/cone function and is currently under trial for efficacy in slowing lesion growth. Despite not being approved as of 2026, ongoing trials indicate potential across several markets.

In April 2026, Kubota Vision announced the successful transfer of its manufacturing site for emixustat hydrochloride, preparing for a full-scale GMP batch to support a compassionate use program in France. The "Emixustat Sales Forecast and Market Size Analysis - 2034" report offers insights into Emixustat's potential, examining usage forecasts across the US, EU4, UK, and Japan. This includes a detailed examination of Emixustat's current market position, future potential, and SWOT analysis.

Key Factors Driving Emixustat Growth

Novel Visual Cycle Modulation Mechanism

• Emixustat inhibits RPE65, reducing toxic byproduct accumulation tied to retinal degeneration.
• Presents a disease-modifying approach, distinct from anti-VEGF therapies focusing on neovascularization.

Unmet Needs in Retinal Diseases

• Evaluated for geographic atrophy due to AMD and Stargardt disease.
• Addresses large AMD patient population and rare disease opportunity in Stargardt disease.

Clinical Signals and Efficacy

• Studies indicate dose-dependent suppression of rod photoreceptor activity but mixed efficacy in GA trials.
• Continued development focus on early disease stages and Stargardt indications.

Oral Administration Advantage

• Oral administration improves patient compliance over injectable therapies.
• Potential for use in early-stage diseases, bolstering maintenance therapy positioning.

Focus on Rare Retinal Diseases

• Particular emphasis on Stargardt disease, offering regulatory incentives and premium pricing potential.

Scope of the Emixustat Market Report

• Provides insights into Emixustat's MoA, dosage, and research activities, particularly in Stargardt disease and diabetic retinopathy.
• Discusses sales forecasts, regulatory milestones, and market positioning across key geographies.
• Incorporates SWOT analysis, competitive landscape, and analysis of emerging therapies.

Methodology and Analytical Perspective

Data for this report is sourced from a mix of databases, research, and industry expert analysis, offering a market assessment across major regions for specific indications to 2034.

Key Highlights

• Projected changes in market dynamics due to strong adoption and broader uptake.
• Competitor analysis indicates potential challenges and opportunities in expanding Emixustat's market presence.
• Insights on pricing, regulatory developments, and market competition form the strategic backbone for decision-making.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15052026004107003653ID1111120158